Literature DB >> 19023204

Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance.

Isabel Sala1, María Belén Sánchez-Saudinós, Laura Molina-Porcel, Estela Lázaro, Ignasi Gich, Jordi Clarimón, Francisco Blanco-Vaca, Rafael Blesa, Teresa Gómez-Isla, Alberto Lleó.   

Abstract

BACKGROUND/AIMS: Elevated total plasma homocysteine (tHcy) is a risk factor for cardiovascular and cerebrovascular disease, and it has also been proposed as an independent risk factor for dementia and Alzheimer's disease (AD). Its relationship with cognitive impairment, however, remains unclear. We aimed to determine the relationship of tHcy levels with clinical diagnoses and cognitive performance in a sample of outpatients with cognitive impairment.
METHODS: Plasma tHcy, folate, vitamin B12 and creatinine levels were assessed in individuals evaluated at the Memory Disorder Unit. Diagnoses included subjective memory complaints (SMC, n = 27), mild cognitive impairment (MCI, n = 142), AD (n = 139) and vascular dementia (VD, n = 17). All patients underwent extensive neuropsychological testing to evaluate attention, memory, language, and visuoconstructional and executive functions, as well as depression and impairments of daily living activities.
RESULTS: tHcy levels did not differ between patients with SMC, MCI, AD or VD. Increased tHcy was associated with worse performance in geometric figure copy and clock drawing tests.
CONCLUSIONS: tHcy levels did not discriminate between diagnostic groups of patients with cognitive impairments. Elevated tHcy levels in these patients appear to have a detrimental effect on visuoconstructional performance. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023204     DOI: 10.1159/000173710

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  9 in total

1.  Novel Therapy of Hyperhomocysteinemia in Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementing Disorders.

Authors:  J Hara; W R Shankle; L W Barrentine; M V Curole
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

2.  X-ray imaging of differential vascular density in MMP-9-/-, PAR-1-/+, hyperhomocysteinemic (CBS-/+) and diabetic (Ins2-/+) mice.

Authors:  S Givvimani; U Sen; N Tyagi; C Munjal; S C Tyagi
Journal:  Arch Physiol Biochem       Date:  2010-09-14       Impact factor: 4.076

Review 3.  Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control.

Authors:  J R Miranda-Massari; M J Gonzalez; F J Jimenez; M Z Allende-Vigo; J Duconge
Journal:  Curr Clin Pharmacol       Date:  2011-11

4.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

5.  Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.

Authors:  Carmen Gasca-Salas; Pedro Clavero; David García-García; José A Obeso; María C Rodríguez-Oroz
Journal:  Hum Brain Mapp       Date:  2015-12-14       Impact factor: 5.038

6.  Effects of differences in serum total homocysteine, folate, and vitamin B12 on cognitive impairment in stroke patients.

Authors:  Bo Jiang; Yumei Chen; Guoen Yao; Cunshan Yao; Hongmei Zhao; Xiangdong Jia; Yunyan Zhang; Junling Ge; Enchao Qiu; Chengyun Ding
Journal:  BMC Neurol       Date:  2014-11-30       Impact factor: 2.474

7.  Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.

Authors:  Estrella Morenas-Rodríguez; Daniel Alcolea; Marc Suárez-Calvet; Laia Muñoz-Llahuna; Eduard Vilaplana; Isabel Sala; Andrea Subirana; Marta Querol-Vilaseca; María Carmona-Iragui; Ignacio Illán-Gala; Roser Ribosa-Nogué; Rafael Blesa; Christian Haass; Juan Fortea; Alberto Lleó
Journal:  Sci Rep       Date:  2019-05-24       Impact factor: 4.379

8.  Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice.

Authors:  A Trueba-Sáiz; C Cavada; A M Fernandez; T Leon; D A González; J Fortea Ormaechea; A Lleó; T Del Ser; A Nuñez; I Torres-Aleman
Journal:  Transl Psychiatry       Date:  2013-12-03       Impact factor: 6.222

9.  Potential Biomarkers for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Ka Young Kim; Ki Young Shin; Keun-A Chang
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.